Cargando…

Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial

OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and nor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hásková, Aneta, Radovnická, Lucie, Petruželková, Lenka, Parkin, Christopher G., Grunberger, George, Horová, Eva, Navrátilová, Vendula, Kádě, Ondřej, Matoulek, Martin, Prázný, Martin, Šoupal, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576432/
https://www.ncbi.nlm.nih.gov/pubmed/32859607
http://dx.doi.org/10.2337/dc20-0112
_version_ 1783598018234155008
author Hásková, Aneta
Radovnická, Lucie
Petruželková, Lenka
Parkin, Christopher G.
Grunberger, George
Horová, Eva
Navrátilová, Vendula
Kádě, Ondřej
Matoulek, Martin
Prázný, Martin
Šoupal, Jan
author_facet Hásková, Aneta
Radovnická, Lucie
Petruželková, Lenka
Parkin, Christopher G.
Grunberger, George
Horová, Eva
Navrátilová, Vendula
Kádě, Ondřej
Matoulek, Martin
Prázný, Martin
Šoupal, Jan
author_sort Hásková, Aneta
collection PubMed
description OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and normal hypoglycemia awareness (Gold score <4) used rtCGM (Guardian Connect Mobile) or isCGM (FreeStyle Libre) during 4 days of physical activity (exercise phase) and in the subsequent 4 weeks at home (home phase). Primary end points were time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) and time in range (3.9–10.0 mmol/L [70–180 mg/dL]). The isCGM group wore an additional masked Enlite sensor (iPro2) for 6 days to check for bias between the different sensors used by the rtCGM and isCGM systems. RESULTS: Sixty adults with T1D (mean age 38 ± 13 years; A1C 62 ± 12 mmol/mol [7.8 ± 1.1%]) were randomized to rtCGM (n = 30) or isCGM (n = 30). All participants completed the study. Percentage of time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) was lower among rtCGM versus isCGM participants in the exercise phase (6.8 ± 5.5% vs. 11.4 ± 8.6%, respectively; P = 0.018) and during the home phase (5.3 ± 2.5% vs. 7.3 ± 4.4%, respectively; P = 0.035). Hypoglycemia differences were significant and most notable during the night. rtCGM participants spent more time in range (3.9–10 mmol/L [70–180 mg/dL]) than isCGM participants throughout both the exercise (78.5 ± 10.2% vs. 69.7 ± 16%, respectively; P = 0.0149) and home (75.6 ± 9.7% vs. 67.4 ± 17.8%, respectively; P = 0.0339) phases. The results were robust to the insignificant bias between rtCGM and isCGM sensors that masked CGM found in the isCGM arm. CONCLUSIONS: rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range in adults with T1D with normal hypoglycemia awareness, demonstrating the value of rtCGM alarms during exercise and in daily diabetes self-management.
format Online
Article
Text
id pubmed-7576432
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-75764322020-11-02 Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial Hásková, Aneta Radovnická, Lucie Petruželková, Lenka Parkin, Christopher G. Grunberger, George Horová, Eva Navrátilová, Vendula Kádě, Ondřej Matoulek, Martin Prázný, Martin Šoupal, Jan Diabetes Care Emerging Technologies: Data Systems and Devices OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and normal hypoglycemia awareness (Gold score <4) used rtCGM (Guardian Connect Mobile) or isCGM (FreeStyle Libre) during 4 days of physical activity (exercise phase) and in the subsequent 4 weeks at home (home phase). Primary end points were time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) and time in range (3.9–10.0 mmol/L [70–180 mg/dL]). The isCGM group wore an additional masked Enlite sensor (iPro2) for 6 days to check for bias between the different sensors used by the rtCGM and isCGM systems. RESULTS: Sixty adults with T1D (mean age 38 ± 13 years; A1C 62 ± 12 mmol/mol [7.8 ± 1.1%]) were randomized to rtCGM (n = 30) or isCGM (n = 30). All participants completed the study. Percentage of time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) was lower among rtCGM versus isCGM participants in the exercise phase (6.8 ± 5.5% vs. 11.4 ± 8.6%, respectively; P = 0.018) and during the home phase (5.3 ± 2.5% vs. 7.3 ± 4.4%, respectively; P = 0.035). Hypoglycemia differences were significant and most notable during the night. rtCGM participants spent more time in range (3.9–10 mmol/L [70–180 mg/dL]) than isCGM participants throughout both the exercise (78.5 ± 10.2% vs. 69.7 ± 16%, respectively; P = 0.0149) and home (75.6 ± 9.7% vs. 67.4 ± 17.8%, respectively; P = 0.0339) phases. The results were robust to the insignificant bias between rtCGM and isCGM sensors that masked CGM found in the isCGM arm. CONCLUSIONS: rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range in adults with T1D with normal hypoglycemia awareness, demonstrating the value of rtCGM alarms during exercise and in daily diabetes self-management. American Diabetes Association 2020-11 2020-08-28 /pmc/articles/PMC7576432/ /pubmed/32859607 http://dx.doi.org/10.2337/dc20-0112 Text en © 2020 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
spellingShingle Emerging Technologies: Data Systems and Devices
Hásková, Aneta
Radovnická, Lucie
Petruželková, Lenka
Parkin, Christopher G.
Grunberger, George
Horová, Eva
Navrátilová, Vendula
Kádě, Ondřej
Matoulek, Martin
Prázný, Martin
Šoupal, Jan
Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title_full Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title_fullStr Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title_full_unstemmed Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title_short Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
title_sort real-time cgm is superior to flash glucose monitoring for glucose control in type 1 diabetes: the corrida randomized controlled trial
topic Emerging Technologies: Data Systems and Devices
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576432/
https://www.ncbi.nlm.nih.gov/pubmed/32859607
http://dx.doi.org/10.2337/dc20-0112
work_keys_str_mv AT haskovaaneta realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT radovnickalucie realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT petruzelkovalenka realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT parkinchristopherg realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT grunbergergeorge realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT horovaeva realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT navratilovavendula realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT kadeondrej realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT matoulekmartin realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT praznymartin realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial
AT soupaljan realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial